SIGA vs. CMPS, ALT, OLMA, HROW, IGMS, ABUS, AVTE, YMAB, CDMO, and APLT
Should you be buying SIGA Technologies stock or one of its competitors? The main competitors of SIGA Technologies include COMPASS Pathways (CMPS), Altimmune (ALT), Olema Pharmaceuticals (OLMA), Harrow (HROW), IGM Biosciences (IGMS), Arbutus Biopharma (ABUS), Aerovate Therapeutics (AVTE), Y-mAbs Therapeutics (YMAB), Avid Bioservices (CDMO), and Applied Therapeutics (APLT). These companies are all part of the "pharmaceutical preparations" industry.
COMPASS Pathways (NASDAQ:CMPS) and SIGA Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.
COMPASS Pathways received 45 more outperform votes than SIGA Technologies when rated by MarketBeat users. Likewise, 76.92% of users gave COMPASS Pathways an outperform vote while only 23.81% of users gave SIGA Technologies an outperform vote.
In the previous week, SIGA Technologies had 8 more articles in the media than COMPASS Pathways. MarketBeat recorded 12 mentions for SIGA Technologies and 4 mentions for COMPASS Pathways. SIGA Technologies' average media sentiment score of 0.77 beat COMPASS Pathways' score of 0.11 indicating that COMPASS Pathways is being referred to more favorably in the media.
COMPASS Pathways has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
SIGA Technologies has higher revenue and earnings than COMPASS Pathways. COMPASS Pathways is trading at a lower price-to-earnings ratio than SIGA Technologies, indicating that it is currently the more affordable of the two stocks.
SIGA Technologies has a net margin of 50.48% compared to SIGA Technologies' net margin of 0.00%. COMPASS Pathways' return on equity of 51.97% beat SIGA Technologies' return on equity.
COMPASS Pathways presently has a consensus target price of $47.40, indicating a potential upside of 504.59%. Given SIGA Technologies' higher probable upside, equities analysts clearly believe COMPASS Pathways is more favorable than SIGA Technologies.
46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 55.4% of SIGA Technologies shares are owned by institutional investors. 4.3% of COMPASS Pathways shares are owned by insiders. Comparatively, 2.2% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
SIGA Technologies beats COMPASS Pathways on 9 of the 16 factors compared between the two stocks.
Get SIGA Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIGA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SIGA Technologies Competitors List
Related Companies and Tools
